Core Insights - The company reported flat like-for-like sales growth of EUR 5.66 billion for the first nine months of 2025, with an ORfA of EUR 267 million [3] - In the third quarter, sales amounted to EUR 1.9 billion, reflecting a decrease of 1.2% like-for-like, and an ORfA performance of EUR 148 million, down EUR 52 million compared to 2024 [3] Sales Outlook - The company revised its 2025 sales outlook from an expected organic sales growth of 2.2% to 4% to a forecast of stable to slightly positive sales growth [4]

Financial Data and Key Metrics Changes - Sales for Q3 2025 totaled $468 million, reflecting an 8% growth on a reported basis and 7% growth organically [18] - Adjusted operating income increased by 14% year-over-year, with adjusted earnings per share (EPS) growing by 25% to $1.79 [13][20] - For the full year 2025, the company expects reported sales to be in the range of $1.84 billion to $1.85 billion, reflecting growth of 7% to 8% [25] Business Line Data and Key Metrics Changes - Cardio and Vascular sales increased by 15% in Q3 2025, driven by new product ramps in electrophysiology and strong demand in neurovascular [21] - Cardiac Rhythm Management and Neuromodulation sales grew by 2% year-over-year in Q3 2025, with expectations for low single-digit growth for the full year [22] - Adjusted net income for Q3 2025 was $63 million, up 27% year-over-year, driven by operational improvements and lower interest expenses [23][24] Market Data and Key Metrics Changes - The company anticipates a 3% to 4% headwind to total company sales in 2026 due to slower market adoption of three new products [15][32] - The expected organic sales growth for 2026 is flat to up 4%, with reported sales expected to decline by 2% to increase by 2% [16][31] Company Strategy and Development Direction - The company remains confident in its long-term growth strategy, focusing on early design wins in high-growth markets [17][35] - A strong product development pipeline is expected to drive above-market organic sales growth in 2027 [34] - The company plans to continue its tuck-in acquisition strategy while maintaining a leverage ratio within the targeted range of 2.5 to 3.5 times [36] Management Comments on Operating Environment and Future Outlook - Management acknowledged recent customer forecast changes impacting the financial outlook but expressed confidence in the long-term strategy [6][8] - The company expects a recovery to market growth in the second half of 2026 as new product headwinds moderate [16][17] - Management emphasized that the recent forecast changes are unusual and not expected to recur [108] Other Important Information - The adjusted effective tax rate for 2025 is expected to be between 17% and 18%, an improvement from previous guidance [24] - The company generated $66 million in cash flow from operations in Q3 2025, with free cash flow remaining flat at $46 million [24] Q&A Session Summary Question: Can you elaborate on the organic growth expectations for the rest of the portfolio? - Management indicated that without new product introductions, the rest of the portfolio is expected to grow at market rates, which is typically 6% to 8% [40] Question: What are the expected headwinds for Cardio and Vascular products? - The headwinds are related to two electrophysiology products with slower-than-anticipated market adoption, impacting growth forecasts [45][46] Question: How confident is the company in returning to market growth in the second half of 2026? - Management expressed confidence due to steady backlog and customer forecasts, despite recent changes [47][49] Question: Were the changes in forecasts known prior to Q3? - Management confirmed that the changes were not known until Q3, which is unusual for multiple products to experience significant forecast changes simultaneously [53][108] Question: Is the decline in neuromodulation sales similar to that in electrophysiology? - Yes, the decline is attributed to slower market adoption among select customers, similar to the dynamics seen in electrophysiology [61][66] Question: How does the company plan to manage profitability in 2026? - The company plans to focus on cost management and operational efficiencies to maintain profitability despite expected sales challenges [98]

智通财经APP获悉，周三，德州仪器(TXN.US)跌6%，报170.08美元。消息面上，德州仪器预计，第四 季度收入将达到42.2亿-45.8亿美元，分析师此前的平均预期为45亿美元，每股收益为1.13至1.39美元， 也逊于市场预期。这一业绩展望表明，在应对日益加剧的贸易紧张局势和不稳定的经济之际，客户正在 放缓订单。 摩根士丹利维持对德州仪器"减持"评级，将目标价从192美元下调至175美元。 由Joseph Moore领衔的分 析师表示："德州仪器在9月份业绩有所增长，我们原本预计12月份会面临一些利润率压力，但营收指引 不佳这一情况出乎我们的意料。" （原标题：美股异动 | 德州仪器(TXN.US)跌6% Q4业绩逊预期遭大行下调目标价） ...

Core Insights - Levi Strauss & Co. raised its full-year revenue and profit forecast after a stronger-than-expected quarterly performance driven by robust denim demand and growth in direct-to-consumer sales [1] - Despite the positive outlook, shares fell over 11% following Morgan Stanley's analysis indicating disappointing profitability flow-through from the upgraded guidance [1] Financial Performance - For Q3, Levi reported earnings of $0.34 per share, exceeding Wall Street's consensus estimate of $0.30 [1] - Revenue increased to $1.54 billion from $1.50 billion year-over-year, surpassing analyst expectations of $1.50 billion [1] Future Guidance - The company now forecasts fiscal 2025 adjusted earnings of $1.27 to $1.32 per share, up from the previous range of $1.25 to $1.30 [2] - Levi raised its reported net revenue growth outlook to around 3%, an increase from the prior estimate of 1% to 2% [2] - Projected organic growth is now roughly 6%, compared to the earlier estimate of 4.5% to 5.5% [2] Margin Expectations - Gross margin is expected to expand by 100 basis points this year, an increase from the prior forecast of 80 basis points [2] - Adjusted EBIT margin is anticipated to remain between 11.4% and 11.6% [2]

Financial Outlook - The company projects a revenue of 1.8 billion CNY for 2025, with a net profit of 100 million CNY and a net profit of 90 million CNY after excluding non-recurring gains and losses [2][3] - The financial targets are internal management indicators and do not constitute a formal profit forecast or commitment to investors [2] Strategic Focus - The management will focus on several key areas to achieve the financial targets, including: - Market-oriented innovation and breakthroughs [3] - Active market expansion to consolidate market share [3] - Implementation of lean management to enhance quality and efficiency [3] - Promotion of expansion projects to increase production capacity [3] - Strengthening cost control to improve overall efficiency [3] - Optimizing internal management for standardized operations [3] Market Engagement - The company is currently focused on the development of liquid product packaging equipment and has no immediate plans to enter other machinery sectors [3] - As of September 15-19, 2025, the company participated in the drinktec 2025 exhibition in Munich, Germany, engaging in technical exchanges and business discussions with global enterprises [3] - The number of shareholders is to be disclosed in the company's regular reports [3]

Core Viewpoint - AECOM reported mixed Q3 results for fiscal 2025, with earnings exceeding estimates while revenues fell short, driven by organic growth in the Americas and International segments [2][3]. Financial Performance - Adjusted earnings per share were $1.34, surpassing the Zacks Consensus Estimate of $1.25 by 7.2% and improving 16% year over year from $1.16 [3]. - Revenue was $4.18 billion, reflecting a 1% year-over-year growth, while net service revenue (NSR) was $1.94 billion, missing the consensus mark of $1.95 billion but increasing 6% year over year [3]. Margins and Profitability - Adjusted operating income rose 13% to $296 million, with adjusted operating margin expanding 90 basis points to 17.1% [4]. - Adjusted EBITDA reached $313 million, up 10% from the prior year, with an adjusted EBITDA margin of 17.6%, growing 110 basis points year over year, marking a record for the company [4]. Segment Highlights - In the Americas segment, NSR rose 8%, with adjusted operating margin expanding 120 basis points to a quarterly record of 20.5% [5]. - The International segment saw NSR increase by 3%, with adjusted operating margin expanding 20 basis points to 11.9%, driven by strong execution in the UK and Middle East, partially offset by a decline in Australia [5]. Balance Sheet and Capital Allocation - AECOM ended the quarter with a net leverage of 0.6x and no debt maturities until 2029 [6]. - Year-to-date free cash flow rose 27% to $551 million, including $262 million in Q3, with $240 million returned to shareholders through repurchases and dividends [6]. Outlook - The company raised its fiscal 2025 outlook, anticipating 5-8% organic NSR growth and adjusted EPS in the range of $5.20-$5.30, indicating a 16% improvement from fiscal 2024 levels [7][8]. - Adjusted EBITDA is expected to be in the range of $1.19-$1.21 billion, indicating 10% year-over-year growth at the midpoint [8].

Core Viewpoint - Carvana's recent earnings report indicates strong performance, with significant revenue and profit growth, raising questions about the sustainability of this trend leading up to the next earnings release [1][2]. Financial Performance - Carvana reported Q2 earnings of $1.28 per share, exceeding the Zacks Consensus Estimate of $1.10 and significantly up from 14 cents per share in the same quarter last year [2]. - Total revenues reached $4.84 billion, surpassing the Zacks Consensus Estimate by 5.62% and reflecting a 42% year-over-year increase [2]. - Total gross profit was $1.06 billion, a 49% increase year-over-year, with gross profit per unit (GPU) rising to $7,426 from $7,049 [3]. Segmental Performance - Retail vehicle sales totaled $3.41 billion, up 41.2% year-over-year, with the number of vehicles sold increasing to 143,280 [4]. - Wholesale vehicle sales reached $1.02 billion, a 42.2% year-over-year increase, with unit sales rising to 72,770 [5]. - Other sales and revenues grew by 47.3% year-over-year to $411 million, with GPU at $2,869 [6]. Financial Position - As of June 30, 2025, Carvana had cash and cash equivalents of $1.86 billion, up from $1.72 billion at the end of 2024, while long-term debt increased slightly to $5.32 billion [7]. Outlook - For Q3 2025, Carvana anticipates a sequential rise in retail unit sales and projects full-year adjusted EBITDA between $2 billion and $2.2 billion, up from $1.38 billion in 2024 [8]. - The consensus estimate for Carvana has shifted upward by 5.65% in the past month, indicating positive sentiment among investors [9]. Industry Context - Carvana operates within the Zacks Internet - Commerce industry, where another player, Booking Holdings, reported revenues of $6.8 billion, reflecting a 16% year-over-year increase [12].

Core Insights - National Vision Holdings, Inc. (EYE) reported second-quarter 2025 adjusted earnings of 18 cents per share, an increase from 15 cents a year ago, surpassing the Zacks Consensus Estimate by 38.5% [1][7] - The company’s GAAP earnings from continuing operations were 11 cents per share, compared to a loss of 1 cent per share in the same quarter last year [1] - Following the earnings announcement, EYE's shares rose by 1.2% [1] Revenue Performance - Net revenues from continuing operations in the second quarter reached $486.4 million, exceeding the Zacks Consensus Estimate by 3.9% [3] - This represents a 7.7% increase from the previous year, driven by comparable store sales growth of 6.5% year over year [3] - Adjusted comparable store sales growth was reported at 5.9% [3] - The company opened eight new America's Best stores, bringing the total store count to 1,240, a 2% increase year over year [3] Margin Analysis - Gross profit for the second quarter increased by 10.8% to $286 million, with gross margin expanding by 2,166 basis points despite a 3.5% rise in the cost of revenues [4] - SG&A expenses rose by 6.8% year over year to $247.2 million [4] - The adjusted operating margin improved to 8%, an increase of 206 basis points year over year [4] Financial Position - At the end of the second quarter, National Vision had cash and cash equivalents of $48.5 million, down from $80 million at the end of the first quarter [5] - Cumulative net cash flow from operating activities was $86.5 million, compared to $75.4 million a year ago [5] Future Outlook - National Vision raised its fiscal 2025 revenue outlook to a range of $1.93 billion to $1.97 billion, up from the previous estimate of $1.92 billion to $1.95 billion [8] - The adjusted EPS estimate for fiscal 2025 is now projected to be between 62 cents and 70 cents, an increase from the previous range of 59 cents to 67 cents [8] - The 53rd week of fiscal 2025 is expected to contribute approximately $35 million to net revenues and nearly $3 million to adjusted operating income [6] Overall Assessment - National Vision achieved better-than-expected results in the second quarter, with both earnings and revenues surpassing estimates [9] - The company has recorded ten consecutive quarters of positive comparable store sales growth, supported by higher average ticket sales and strength in its managed care cohort [9] - Margin expansion during the quarter is viewed positively, alongside successful execution of transformation and cost reduction initiatives [10]

Core Viewpoint - Xylem Inc. reported strong financial performance for the fiscal year 2024, with total revenue reaching $8.6 billion, representing a 16% year-over-year growth, driven by robust market demand and operational efficiency [1][2][6]. Financial Performance Summary - In Q4 2024, Xylem achieved total revenue of $2.3 billion, with a net income of $326 million, resulting in an earnings per share (EPS) of $1.34, which is a 22% increase [2][4]. - The adjusted net income for Q4 2024 was $287 million, with an adjusted EPS of $1.18, reflecting a 19% growth [4]. - For the entire year of 2024, the net income was $890 million, with an EPS of $3.65, marking a 31% increase year-over-year [3][6]. Cost and Profitability Insights - The adjusted EBITDA margin for Q4 2024 was 21.0%, an increase of 140 basis points compared to the previous year, attributed to productivity improvements and effective pricing strategies [5]. - The company experienced a net profit margin increase of 190 basis points to 14.5% in Q4 2024, despite facing challenges from restructuring costs and previous year’s tax benefits [4]. Dividend Announcement - The board of directors announced a quarterly dividend of $0.40 per share for Q1 2025, representing an 11% increase from the previous dividend [5]. 2025 Financial Outlook - Xylem projects total revenue for fiscal year 2025 to be between $8.6 billion and $8.7 billion, indicating a growth of 0% to 2% based on reported figures, and 3% to 4% on an organic basis [7]. - The adjusted EBITDA margin for 2025 is expected to improve to between 21.3% and 21.8%, reflecting an increase of 70 to 120 basis points compared to 2024 [7]. - The company anticipates a free cash flow margin of 9% to 10% for the year [7].